GET DAILY SIGNALSRafael Holdings (RFL) Shares Decline 27.6% Over 30 Days After Phase 3 Setback
Key Takeaways
- Rafael Holdings (RFL) shares declined roughly 27.6% over the last 30 days, falling from about $1.52 to around $1.10.
- The slide extends a sell-off that began after the company's pivotal Phase 3 TransportNPC trial missed its primary endpoint in late September.
- Fiscal Q4 and full-year results reported on October 29 showed revenue of about $874,000 and a net loss of roughly $29.6 million, alongside going-concern disclosure.
- Cash and cash equivalents fell to approximately $22.1 million at fiscal year-end, down from about $52.8 million a year earlier.
- The company submitted a New Drug Application (NDA) to the FDA for remibetadex in late October, a key regulatory milestone despite the mixed trial data.
- Several law firms announced investigations into potential securities claims, adding to investor uncertainty.
- For additional data, explore this ticker's Price Targets, Earnings, and Forecast pages.
- Discover automated trading ideas through Trending AI Robots.
Rafael Holdings (RFL) Company Background
Rafael Holdings, Inc. is a Newark, New Jersey-based biopharmaceutical holding company that owns interests in clinical and early-stage pharmaceutical and medical-device companies in the United States and Israel. It operates across three segments: Healthcare, Infusion Technology, and Real Estate. The company's lead asset is Trappsol Cyclo (remibetadex), an intravenous hydroxypropyl-beta-cyclodextrin being developed for Niemann-Pick Disease Type C (NPC), a rare, progressive and often fatal genetic disorder. Its pipeline also includes earlier-stage oncology programs such as CPI-613 (devimistat) and Promitil.
As a clinical-stage company with limited product revenue, RFL is closely followed by investors for binary catalysts tied to its drug-development milestones and regulatory progress. Because it has no approved products generating meaningful sales, the stock is highly sensitive to clinical trial results, FDA interactions, and its ability to secure additional financing. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent Stock Price Movement: Last 30 Days and Quarter
Over the last 30 days, Rafael Holdings shares have fallen approximately 27.6%, declining from a closing price of about $1.52 to around $1.10. The move was not a single-day event but rather a steady drift lower punctuated by renewed selling around the company's late-October earnings report and regulatory update. One thing that stands out is how the broader three-month trend has been considerably weaker, with the stock down roughly 44% from about $1.97 in mid-August through early November.
The most severe single-session move occurred on September 30, when shares fell about 35% to close near $1.32 after the company disclosed that its Phase 3 TransportNPC study did not achieve statistical significance on its primary endpoint. That gap down reset the stock's valuation and set the tone for the subsequent gradual decline.
Factors Behind the 30-Day Decline
The most significant 30-day catalyst was the company's October 29 announcement of fiscal fourth-quarter and full-year 2026 results, combined with its corporate update. Revenue for the fiscal year ended July 31, 2026 was approximately $874,000, down from about $917,000 in the prior year, while the net loss attributable to the company was roughly $29.6 million. Critically, management disclosed that cash and cash equivalents had declined to about $22.1 million from roughly $52.8 million a year earlier and that, based on expected expenses tied to the FDA review and potential commercialization of remibetadex, there is substantial doubt about the company's ability to continue as a going concern without additional financing.
Around the same time, the company confirmed that its subsidiary Cyclo Therapeutics had submitted an NDA to the FDA for remibetadex for the treatment of NPC. While a meaningful regulatory step, the filing was received cautiously because it rests on a trial that missed its primary endpoint, even though prespecified subgroup and survival analyses showed favorable signals. I’m watching this closely as the financing picture evolves.
Compounding the pressure, several law firms — including Pomerantz LLP and Bronstein, Gewirtz & Grossman — announced investigations into potential securities claims on behalf of investors. The resulting uncertainty, combined with the reduced cash position and a lack of near-term positive catalysts, kept selling pressure elevated through the period.
Quarterly Performance Drivers
The quarterly decline was anchored by the September 30 disclosure of topline results from the pivotal Phase 3 TransportNPC study in 94 patients with NPC. The trial's primary endpoint — change in the four-domain NPC Clinical Severity Scale at Week 96 — did not reach statistical significance in the overall population (p=0.19). Investors had positioned for a clearer outcome, and the miss triggered a single-session drop of about 35%.
The data were not uniformly negative. A prespecified analysis of patients receiving background miglustat and/or leucine therapy — roughly 83% of the study population — showed a statistically significant 71% relative reduction in disease progression (p=0.046), and an overall survival analysis suggested a substantial reduction in mortality risk in infantile-onset patients compared with matched external controls. Despite these supportive signals, the broader market focused on the missed primary endpoint and the heightened regulatory and financing risk it introduced, driving the multi-month decline that followed.
Forward-Looking Considerations for Investors
Investors are likely to monitor several forward-looking factors. The first is the FDA's response to the remibetadex NDA, including whether the agency accepts the application for filing and whether it grants priority review or designates a PDUFA target action date. The strength of the subgroup and survival data relative to the missed primary endpoint will be central to that decision. From what I see, financing remains a key variable given the cash position and going-concern language.
Litigation developments tied to the announced law-firm investigations, any further clinical or regulatory updates, and broader biotech-sector risk appetite are also likely to shape sentiment. These factors carry inherent uncertainty, and none of them should be read as a prediction of future share-price direction.
Using AI Tools for Trading Insights
In my view, tools like Tickeron’s AI Trading Bots can help investors explore systematic approaches to volatile names such as RFL. The platform offers a range of automated strategies that track market patterns across thousands of tickers, allowing users to review performance metrics and consider how different bots align with their own risk parameters. This kind of resource serves as a starting point for those interested in rules-based ideas rather than providing direct recommendations.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
RFL in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 02, 2026
RFL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 32 of 35 cases where RFL's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where RFL's RSI Indicator exited the oversold zone, 26 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for RFL just turned positive on November 05, 2026. Looking at past instances where RFL's MACD turned positive, the stock continued to rise in 37 of 49 cases over the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RFL as a result. In 80 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The 50-day moving average for RFL moved below the 200-day moving average on November 10, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RFL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for RFL entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. RFL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.717) is normal, around the industry mean (2.188). P/E Ratio (-1.444) is within average values for comparable stocks, (54.152). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (0.683). Dividend Yield (0.000) settles around the average of (0.107) among similar stocks. RFL's P/S Ratio (103.093) is very high in comparison to the industry average of (5.807).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RFL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of telecommunication services
Industry RealEstateDevelopment
Advertisement